Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

The chronic lymphocytic leukemia therapeutics market is expected to grow at a compound annual growth rate of 7% from 2025 to ...

Data suggest that “venetoclax usage should be avoided in the general relapsed or refractory multiple myeloma population,” the researchers wrote.